INTERFERON (IFN)-FREE ALISPORIVIR (ALV) HAS A BETTER OVERALL SAFETY PROFILE COMPARED TO IFN-CONTAINING TREATMENT: A POOLED ANALYSIS OF THE ALV DEVELOPMENT PROGRAM

被引：10

作者：

Griffel, L. ^{[1
]}

Bao, W. ^{[2
]}

Orsenigo, R. ^{[3
]}

Guo, V. ^{[2
]}

Wu, M. ^{[2
]}

Loeffler, J. ^{[3
]}

Brass, C. ^{[2
]}

Avila, C. ^{[3
]}

Naoumov, N. V. ^{[3
]}

机构：

[1] Novartis, E Hanover, NJ USA

[2] Novartis Pharmaceut, E Hanover, NJ USA

[3] Novartis Pharma AG, Basel, Switzerland

来源：

关键词：

D O I：

10.1016/S0168-8278(13)60823-5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

821

引用

页码：S336 / S337

页数：2